Probatebeta
Target

TOP1

DNA topoisomerase 1

As of the edition of 20 October 2026, TOP1 (DNA topoisomerase 1, UniProt P11387) has 30 drugs tested at it and 33 companies on the list, 9 on route A and 6 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P11387
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
Inside the cell
Solved structures
15
Disease areas
Cancer; Digestive system; Lungs and airways; Hormones; Skin and connective tissue; Urinary and reproductive; Pregnancy and women's health; Nervous system
Registered trials of its drugs
2,184

Drugs at this target

StatusCount
Marketed7
Active5
Went quiet10
Stopped7
Status not established1
Total30
DrugStatusFurthest phaseUS protection
IrinotecanMarketedPhase 4none listed
TopotecanMarketedPhase 4none listed
Trastuzumab deruxtecanMarketedPhase 4Ends 2031
Sacituzumab govitecanMarketedPhase 4Ends 2032
Sacituzumab tirumotecanActivePhase 3none listed
Datopotamab deruxtecanMarketedPhase 4Ends 2037
Patritumab deruxtecanActivePhase 3none listed
Irinotecan sucrosofateStoppedPhase 3none listed
RubitecanStoppedPhase 3none listed
AclarubicinActivePhase 3none listed
ExatecanWent quietPhase 3none listed
BecatecarinStoppedPhase 3none listed

12 of 30 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A9
Route B6
Engaged16
Undetermined2
Total on the list33
Three companies on route A or B, with the route only
CompanyRoute
Gilead SciencesRoute B
GSKRoute A
AstraZenecaRoute B

The other 30 companies at TOP1

In the product

33 companies in all; 30 are not named here, and no score is.

See the 33 companies at TOP1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at TOP1

Other targets in cancer

Companies holding approvals at TOP1